For years, the Chinese branch of a major European-based multinational pharmaceutical company saved significant money by submitting its proposals for the approval of new medicines in English to the Chinese government, even though the ‘‘rule’’ stated the application should be in Chinese. To write the application in Chinese would be very expensive, requiring new computers, keyboards, software, and the like.